Hab Pharmaceuticals And Research Limited
Hab Pharmaceuticals And Research Limited is a Public Non-govt company company incorporated in 1997 and based in Maharashtra, India. Hab Pharmaceuticals And Research Limited operates in Other (NIC 99999) with authorized capital of ₹10.00 Cr and paid-up capital of ₹3.13 Cr. For 2023-24, the company reported revenue of ₹376.02 Cr and profit after tax of ₹0. RegisterKaro's Compliance Health Score for the company is 35/100 (grade F), reflecting a weak compliance posture.
Quick facts
Directors
LockedDirectors, DINs & appointment history for Hab Pharmaceuticals And Research Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
MCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | +34d | filed |
| MGT-7 | FY2024-25 | 20 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | 0d | filed |
| MGT-7 | FY2023-24 | 23 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | 0d | filed |
| MGT-7 | FY2022-23 | 24 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Hab Pharmaceuticals And Research Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 868645450 | ICICI Bank Ltd(Bank) | ₹16.65 Cr | 27 Jan 2023 | Open |
| 236719639 | HDFC Bank Ltd(Bank) | ₹14.23 Cr | 12 Mar 2021 | Open |
| 477665654 | State Bank of India(Bank) | ₹21.86 Cr | 12 Mar 2022 | Open |
| 339091609 | Kotak Mahindra Bank Ltd(Bank) | ₹23.03 Cr | 12 Mar 2021 | Open |
| 838179917 | Axis Bank Ltd(Bank) | ₹5.79 Cr | 12 Mar 2022 | Open |
Charge IDs, lenders & amounts for Hab Pharmaceuticals And Research Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
MCA| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| 2023-24 | — | ||||
| 2016-17 | — |
Detailed Financials
2 FYs| Line item | 2023-24 | 2016-17 |
|---|---|---|
| Income statement | ||
| Revenue from operations | ||
| Other income | ||
| Total income | ||
| Total expenses | ||
| Profit before tax | ||
| Profit / (Loss) after tax | ||
| Balance sheet | ||
| Equity / Net worth | ||
| Borrowings | ||
| Current liabilities | ||
| Total liabilities | ||
| Current assets | ||
| Cash & equivalents | ||
| Total assets | ||
| Employees | — | — |
Cash-flow statement renders when the AOC-4 XBRL Cash Flow context is parsed during the extract phase.
Compounded Annual Growth Rate
| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue2023-24 | +305.0% | — | — | |
| Profit after Tax2023-24 | -373.0% | — | — | |
| Net Worth2023-24 | +359.0% | — | — |
Financial Ratios
| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| 2016-17 | +1.60% | — | +5.08% | +1.87% | 2.72 | |||
| 2023-24 | +0.00% | +507.08% | +0.00% | +0.00% | — |
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 2 | 1,36,81,643 | 91.92% |
| Institutional Investors | 1 | 3,88,953 | 2.61% |
| Public & Others | 27 | 8,13,224 | 5.46% |
Promoter, institutional & public holding for Hab Pharmaceuticals And Research Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
56 peersEvents & timeline
2External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.